<SEC-DOCUMENT>0001213900-21-009271.txt : 20210216
<SEC-HEADER>0001213900-21-009271.hdr.sgml : 20210216
<ACCEPTANCE-DATETIME>20210216083732
ACCESSION NUMBER:		0001213900-21-009271
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20210216
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210216
DATE AS OF CHANGE:		20210216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Wize Pharma, Inc.
		CENTRAL INDEX KEY:			0001218683
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				880445167
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-52545
		FILM NUMBER:		21632881

	BUSINESS ADDRESS:	
		STREET 1:		24 HANAGAR ST
		CITY:			HOD HASHARON
		STATE:			L3
		ZIP:			4527713
		BUSINESS PHONE:		972 472 260 0536

	MAIL ADDRESS:	
		STREET 1:		24 HANAGAR ST
		CITY:			HOD HASHARON
		STATE:			L3
		ZIP:			4527713

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	OphthaliX, Inc.
		DATE OF NAME CHANGE:	20120207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DENALI CONCRETE MANAGEMENT INC
		DATE OF NAME CHANGE:	20030213
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea135721-8k_wizepharma.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>WASHINGTON, D.C. &nbsp;20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Date of report (Date of earliest event reported)
<B>February 16, 2021</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>Wize Pharma, Inc.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Exact Name of Registrant as Specified in
its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>000-52545</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>88-0445167</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State or other jurisdiction <BR>
of incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(IRS Employer <BR>
Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>24 Hanagar Street, Hod Hasharon, Israel</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 49%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4527708</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address of principal executive offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">Registrant&rsquo;s telephone number, including
area code: &nbsp;<B>+(972) 72-260-0536</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 24px; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written communications pursuant to Rule 425 under the Securities Act</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting material pursuant to Rule 14a-12 under the Exchange Act</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Securities registered pursuant to Section
12(b) of the Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title of each class</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Trading Symbol(s)</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1.5pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Name of each exchange on which registered</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Emerging growth company&nbsp;&#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.&nbsp; &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7.01 Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">As previously reported, on February 1, 2021,
Wize Pharma, Inc. (the &ldquo;Company&rdquo; or &ldquo;Wize&rdquo;) lodged a Bidder&rsquo;s Statement with the Australian Securities
and Investments Commission to commence its off-market takeover offer under applicable Australian laws (the &ldquo;Offer&rdquo;)
to acquire all of the outstanding shares (the &ldquo;Cosmos Shares&rdquo;) of Cosmos Capital Limited, a digital infrastructure
provider based in&nbsp;Sydney, Australia (&ldquo;Cosmos&rdquo;), in connection with the Bid Implementation Agreement by and between
the Company and Cosmos, dated December 30, 2020 (as amended, the BIA&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">On February 16, 2021,
the Company issued a press release announcing that the Offer became unconditional and that it plans to consummate the transactions
contemplated by the BIA and the Offer on or about March 9, 2021. A copy of the press release is attached hereto as Exhibit 99.1
and is incorporated herein by reference.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="background-color: white"><B>CAUTIONARY
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1cm; background-color: white"><I>&nbsp;</I></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt"><FONT STYLE="background-color: white">Wize
cautions that statements in this report that are not a description of historical fact are forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words
referencing future events or circumstances such as &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;believe,&rdquo; and &ldquo;will,&rdquo; among others. Because such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements
are based upon Wize&rsquo;s current expectations and involve assumptions that may never materialize or may prove to be incorrect.
Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a
result of various risks and uncertainties, which include, without limitation, the possibility that Wize will not consummate the
transactions with Cosmos and the PIPE investors or, if Wize does consummate such transactions, that it will not receive the benefits
Wize planned to achieve from such transactions; the possibility that Wize will enter into a transaction with respect to its LO2A
business that will ultimately benefit holders of the CVRs; Wize&rsquo;s expectations regarding the capitalization, resources and
ownership structure of the post-closing combined company; the nature, strategy and focus of the post-closing combined company;
the executive officer and board structure of the post-closing combined company; and the expectations regarding acceptance of the
Offer by the Cosmos shareholders. More detailed information about the risks and uncertainties affecting Wize is contained under
the heading &ldquo;Risk Factors&rdquo; included in Wize&rsquo;s Annual Report on Form 10-K filed with the SEC on&nbsp;</FONT>March
30, 2020<FONT STYLE="background-color: white">, and in other filings that Wize has made and may make with the SEC in the future.
Wize and/or Cosmos may not actually consummate the proposed transaction, or any plans or product development goals in a timely
manner, if at all, or otherwise carry out the intentions or meet the expectations or projections disclosed in Wize&rsquo;s forward-looking
statements, and one should not place undue reliance on these forward-looking statements, which speak only as of the date on which
they were made. Because such statements are subject to risks and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Wize undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were made, except as may be required by law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 9.01 Financial Statements and Exhibits.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(d) Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 90%"><A HREF="ea135721ex99-1_wizepharma.htm"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Press Release, dated February 16, 2021: Wize Pharma&rsquo;s Takeover Offer for Cosmos Capital Declared Unconditional</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 36pt">Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Wize Pharma, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 35%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Or Eisenberg</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Or Eisenberg</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: February 16, 2021</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea135721ex99-1_wizepharma.htm
<DESCRIPTION>PRESS RELEASE, DATED FEBRUARY 16, 2021: WIZE PHARMA'S TAKEOVER OFFER FOR COSMOS CAPITAL DECLARED UNCONDITIONAL
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Wize Pharma&rsquo;s Takeover Offer for
Cosmos Capital Declared Unconditional</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><I>Transaction expected to close on March
9, 2021</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">HOD HASHARON, Israel, February 16, 2021
- Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders,
today announced that it has declared its previously announced off-market takeover offer (&ldquo;Offer&rdquo;) for all of the ordinary
shares in Cosmos Capital Limited, a leading digital infrastructure provider based in Sydney, Australia (&ldquo;Cosmos&rdquo;),
free from all of the conditions set out in the Offer and, accordingly, the Offer has become unconditional. A formal notice of the
unconditionality of the Offer, as required under section 650F of the Corporations Act 2001 (Australia), is attached as Annexure
A below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Based on, among others, information provided by Automic Pty
Ltd., the depositary for the Offer, holders of approximately 94.5% of Cosmos shares, accepted (or undertook to accept) the Offer
as of 7.00pm (Sydney time) on February 15, 2021. Accordingly, and since the minimum acceptance condition of 90% was essentially
satisfied, Wize has determined to declare the Offer unconditional and plans to consummate the transactions contemplated by the
Bid Implementation Agreement between Wize and Cosmos, dated December 30, 2020 (as amended, the &ldquo;BIA&rdquo;) on or about March
9, 2021 (the &ldquo;BIA Closing&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Offer will currently remain open for
acceptance until 7.00pm (Sydney time) on March 11, 2021 (but Wize may determine to extend such period, even after the BIA Closing,
in order to allow additional Cosmos shareholders to accept the Offer). <B>Wize strongly encourages all remaining Cosmos shareholders
to accept the Offer</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Noam Danenberg, CEO of Wize, stated, &ldquo;We are very pleased
that holders of nearly all Cosmos shares have accepted Wize&rsquo;s off-market takeover offer. We strongly believe the transaction
will maximize value for shareholders of both Wize and Cosmos and we look forward to the closing of the transaction before the end
of the first quarter.&rdquo;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">James Manning, CEO and founder of Cosmos, commented, &ldquo;This
shareholder acceptance brings Cosmos one step closer to being a publicly traded company as blockchain technology and cryptocurrencies
continue to gain value and recognition both in industry and the capital markets.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Wize Pharma</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wize Pharma, Inc. is a clinical-stage biopharmaceutical
company currently focused on the treatment of ophthalmic disorders, including dry eye syndrome (DES). Wize has in-licensed certain
rights to purchase, market, sell and distribute a formula known as LO2A, a drug developed for the treatment of DES, and other ophthalmological
illnesses, including CCh and Sj&ouml;gren&rsquo;s syndrome (Sj&ouml;gren&rsquo;s).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wize recently reported topline results
from its Phase IV clinical trial of LO2A for the symptomatic treatment of DES in patients with Sj&ouml;gren&rsquo;s syndrome, in which
LO2A met its primary endpoint of non-inferiority vs. comparator. LO2A demonstrated clinically meaningful improvement in both the
signs and symptoms of DES in patients suffering from Sj&ouml;gren&rsquo;s. A numeric advantage was evident in both the signs and symptoms
of DES for patients using LO2A vs. the comparator in the subgroup of patients with primary Sj&ouml;gren&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">LO2A is currently registered and marketed
by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES, CCh and Sj&ouml;gren&rsquo;s
and in the Netherlands for the treatment of DES and Sj&ouml;gren&rsquo;s.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>About Cosmos Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Cosmos Capital is a digital infrastructure
provider, with diversified operations across Cryptocurrency Mining and Digital Asset Management. Headquartered in Sydney, Australia
and operating across the USA and Australia, Cosmos&rsquo; mission is to build a bridge between the rapidly emerging digital asset industry
and traditional capital markets, with a strong focus on shareholder returns. Cosmos matches energy infrastructure with next-generation
mobile data centre solutions, enabling the proliferation of blockchain technology. Cosmos is an unlisted Australian public company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Forward Looking Statements </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Wize cautions you that statements in this
press release that are not a description of historical fact are forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances
such as &ldquo;expect,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;believe,&rdquo; and &ldquo;will,&rdquo;
among others. For example, when we discuss the expected closing of the Offer and the BIA, we are using a forward-looking statement.
Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied
by such forward-looking statements. These forward-looking statements are based upon Wize&rsquo;s current expectations and involve assumptions
that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation,
the possibility that we will not consummate the transactions with Cosmos or, if we do consummate such transactions, that we will
not receive the benefits we planned to achieve from such transactions; the possibility that Wize will enter into a transaction
with respect to its LO2A business that will ultimately benefit holders of the CVRs; our expectations regarding the capitalization,
resources and ownership structure of the post-closing combined company; the nature, strategy and focus of the post-closing combined
company; the executive officer and board structure of the post-closing combined company; and the expectations regarding acceptance
of the Offer by the Cosmos shareholders. More detailed information about the risks and uncertainties affecting Wize is contained
under the heading &ldquo;Risk Factors&rdquo; included in Wize&rsquo;s Annual Report on Form 10-K filed with the SEC on March 30, 2020,
and in other filings that Wize has made and may make with the SEC in the future. Wize and/or Cosmos may not actually consummate
the proposed transaction, or any plans or product development goals in a timely manner, if at all, or otherwise carry out the intentions
or meet the expectations or projections disclosed in our forward-looking statements, and you should not place undue reliance on
these forward-looking statements, which speak only as of the date on which they were made. Because such statements are subject
to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.
Wize and Cosmos undertake no obligation to update such statements to reflect events that occur or circumstances that exist after
the date on which they were made, except as may be required by law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>The contents of any website or hyperlinks
mentioned in this press release are for informational purposes and the contents thereof are not part of this press release.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">For all investor enquiries, please contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Or Eisenberg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">+972-72-260-0536</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">or@wizepharma.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Annexure A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cosmos
Capital Limited ACN 636 458 912</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Offer
for ordinary shares by Wize Pharma, Inc</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Notice
under section 650F of the <I>Corporations Act </I>2001</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Wize
Pharma, Inc (<B>Wize</B>) has made offers under an off-market takeover bid (<B>Offers</B>) for all of the ordinary shares in
Cosmos Capital Limited ACN 636 458 912 (<B>Cosmos</B>). The Offers are contained in Wize&rsquo;s bidder&rsquo;s statement
dated 1 February 2021 (<B>Bidder&rsquo;s Statement</B>).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Wize
gives notice under section 650F(1) of the <I>Corporations Act </I>2001 (Cth), declaring that each of those Offers and each
contract formed by the acceptance of those Offers are free from each of the conditions contained in section 12 of the
Bidder&rsquo;s Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">At
the date of this notice the voting power of Wize in Cosmos was approximately 94.56%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Dated:
16 February 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<IMG SRC="ex99-1_001.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 40%"><DIV STYLE="border-top: Black 1.5pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">For
and on behalf of Wize Pharma, Inc</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  L /,# 2(  A$! Q$!_\0
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MMG?\%OOVD]1_:&^*6KI8&+]GOX6ZOJVB_"'POX=2W<Z1\/SXLB3PSXDT30M
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M*H-O++^Z!D)!W(!\Y?Y<CK@B+-K5I_"OAM\7\3[7_+SI_+_>+OO_ %V-H-&
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645)12]G3_D7WDN<TW[__ )*__DC_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
